Large Molecule Patents
Rituxan is a drug owned by Genentech, Inc.. It is protect by 4 US patents. Given below is the list of those patents along with their expiration dates.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10759866 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(3 years from now) | Active |
| US10450379 | GENENTECH, INC. | Method for treating joint damage |
Nov, 2026
(1 year, 10 months from now) | Active |
| US10654940 | GENENTECH, INC. | Method for treating joint damage |
Nov, 2026
(1 year, 10 months from now) | Active |
| US7976838 | GENENTECH, INC. | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-α inhibitor |
Jun, 2025
(6 months from now) | Active |
Rituxan's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
About Rituxan
Active Ingredients:
Rituxan contains Rituximab as an active ingredient
Approval Date:
Rituxan was first approved for market use on 26 Nov, 1997.
Dosage:
Rituxan is available in 2 strengths and the following dosage forms are - Injection form for Intravenous use, Injection form for Intravenous use.
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG/10ML (10MG/ML) | Injection | Rx | Intravenous |
| 100MG/10ML (10MG/ML) | Injection | Rx | Intravenous |
| 100MG/10ML (10MG/ML) | Injection | Rx | Intravenous |
| 500MG/50ML (10MG/ML) | Injection | Rx | Intravenous |
| 500MG/50ML (10MG/ML) | Injection | Rx | Intravenous |
| 500MG/50ML (10MG/ML) | Injection | Rx | Intravenous |